NAD+ Precursors (NMN/NR) for Parkinson's Disease

Migration, Crosslink

📖

NAD+ Precursors (NMN/NR) for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-nmn-nad-precursor-park

📖 Wiki Page

therapeutic1822 wordssynced 2026-04-02

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursors (NMN/NR) for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Substrate for Complex I</td>
</tr>
<tr>
<td class="label">Sirtuin activity</td>
<td>NAD+-dependent deacetylases</td>
</tr>
<tr>
<td class="label">DNA repair</td>
<td>PARP substrate availability</td>
</tr>
<tr>
<td class="label">Mitophagy</td>
<td>PGC-1α activation</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>SIRT1-mediated NF-κB inhibition</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Schondorf et al., 2014</td>
<td>PINK1 knockdown</td>
</tr>
<tr>
<td class="label">Brakedal et al., 2022</td>
<td>PD patient neurons</td>
</tr>
<tr>
<td class="label">Girgis et al., 2024</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wang et al., 2023</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">Chen et al., 2022</td>
<td>Alpha-synuclein model</td>
</tr>
<tr>
<td class="label">Ito et al., 2023</td>
<td>Multiple PD models</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT03061812</td>
<td>NR</td>
</tr>
<t

...

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursors (NMN/NR) for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Substrate for Complex I</td>
</tr>
<tr>
<td class="label">Sirtuin activity</td>
<td>NAD+-dependent deacetylases</td>
</tr>
<tr>
<td class="label">DNA repair</td>
<td>PARP substrate availability</td>
</tr>
<tr>
<td class="label">Mitophagy</td>
<td>PGC-1α activation</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>SIRT1-mediated NF-κB inhibition</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Schondorf et al., 2014</td>
<td>PINK1 knockdown</td>
</tr>
<tr>
<td class="label">Brakedal et al., 2022</td>
<td>PD patient neurons</td>
</tr>
<tr>
<td class="label">Girgis et al., 2024</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wang et al., 2023</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">Chen et al., 2022</td>
<td>Alpha-synuclein model</td>
</tr>
<tr>
<td class="label">Ito et al., 2023</td>
<td>Multiple PD models</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT03061812</td>
<td>NR</td>
</tr>
<tr>
<td class="label">NCT03816084</td>
<td>NR</td>
</tr>
<tr>
<td class="label">NCT06162013</td>
<td>NAD+ precursors</td>
</tr>
<tr>
<td class="label">NCT04436533</td>
<td>NAD+ precursors</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NR (Nicotinamide Riboside)</td>
<td>250-500 mg</td>
</tr>
<tr>
<td class="label">NMN (Nicotinamide Mononucleotide)</td>
<td>100-250 mg</td>
</tr>
<tr>
<td class="label">Combination (NR + NMN)</td>
<td>NR 250 mg + NMN 100 mg</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">NR + Resveratrol</td>
<td>SIRT1 activation synergy</td>
</tr>
<tr>
<td class="label">NR + CoQ10</td>
<td>Mitochondrial support</td>
</tr>
<tr>
<td class="label">NMN + Spermidine</td>
<td>Autophagy enhancement</td>
</tr>
<tr>
<td class="label">NR + PGC-1α activators</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">NR + Melatonin</td>
<td>SIRT3 activation, sleep benefit</td>
</tr>
</table>

Parkinson's disease (PD) is characterized by progressive dopaminergic neuron loss in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) and the accumulation of [Lewy bodies](/entities/lewy-bodies) composed of misfolded [alpha-synuclein](/proteins/alpha-synuclein). A central pathological mechanism is mitochondrial dysfunction, which is intimately linked to cellular NAD+ (nicotinamide adenine dinucleotide) depletion. NAD+ boosting therapies, particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have emerged as promising disease-modifying strategies that target the metabolic root of neurodegeneration.

This page provides comprehensive coverage of NAD+ precursor therapy specifically for Parkinson's disease, covering the mechanistic rationale, preclinical evidence, clinical trial data, dosing recommendations, and combination approaches.

NAD+ Deficiency in Parkinson's Disease

The Vicious Cycle of NAD+ Depletion

NAD+ levels decline naturally with age, but this decline is dramatically accelerated in PD through multiple converging mechanisms[@jiang2021]:

Mermaid diagram (expand to render)

Key mechanisms driving NAD+ depletion in PD:

Complex I Inhibition: Mitochondrial complex I deficiency is a hallmark of sporadic PD["@schondorf2014"]. Complex I oxidizes NADH to NAD+, and its dysfunction impairs NAD+ regeneration through the electron transport chain.

PARP Overactivation: Increased DNA damage in PD neurons triggers PARP (poly ADP-ribose polymerase) activation, consuming NAD+ in poly(ADP-ribosylation) reactions["@meyer2022"].

CD38 Upregulation: CD38 and CD157 ectoenzymes hydrolyze NAD+ to ADP-ribose. Their expression increases in aging and neurodegeneration, accelerating NAD+ loss.

Reduced Salvage Pathway Efficiency: NMN adenylyltransferase (NMNAT) and nicotinamide phosphoribosyltransferase (NAMPT) efficiency decline with age, limiting the cell's ability to recycle NAD+ from nicotinamide.

Alpha-Synuclein Toxicity: Alpha-synuclein aggregation directly interferes with mitochondrial function and sirtuin activity, creating a feed-forward cycle of dysfunction.

Clinical Evidence of NAD+ Deficiency

Post-mortem studies of PD substantia nigra show:

Significant reductions in NAD+ levels compared to age-matched controls
Decreased NAMPT expression
Impaired mitochondrial respiratory function
Elevated DNA damage markers

Patient-derived neurons from individuals with sporadic PD exhibit severe NAD+ depletion, leading to impaired mitochondrial function and increased vulnerability to metabolic stress[@schondorf2014].

Therapeutic Rationale

Why NAD+ Precursors?

Restoring cellular NAD+ levels addresses multiple pathological pathways simultaneously:

NMN vs. NR: Comparative Pharmacology

Both NMN and NR are efficient NAD+ precursors, but they differ in their metabolic pathways and clinical profiles:

Mermaid diagram (expand to render)

Nicotinamide Riboside (NR):

Converted to NMN by NR kinases (NRK1/NRK2)
Well-documented safety profile in human trials
Demonstrated to increase blood and CSF NAD+ levels
Available as dietary supplement (Niagen™, Tru Niagen™)
Shown to rescue mitochondrial dysfunction in PINK1 models["@schondorf2014"]

Nicotinamide Mononucleotide (NMN):

Direct NAD+ precursor, one metabolic step closer to NAD+
More potent at raising NAD+ levels in some studies
Requires NMNAT for conversion to NAD+
Strong preclinical evidence in PD models["@wang2023"]
Currently in multiple clinical trials

Preclinical Evidence in PD Models

Nicotinamide Riboside

Nicotinamide Mononucleotide

Mechanistic Pathways

SIRT1-PGC-1α Axis:

NAD+ restoration activates SIRT1
SIRT1 deacetylates and activates PGC-1α
Enhanced mitochondrial biogenesis[@hao2023]
Improved mitophagy capacity
Reduced oxidative stress

Neuroinflammation:

SIRT1 activation deacetylates NF-κB
Reduced pro-inflammatory cytokine production
Microglial modulation toward anti-inflammatory phenotype[@liu2023]

DNA Repair:

PARP has sufficient NAD+ substrate
Enhanced base excision repair
Reduced accumulation of DNA damage

Clinical Trials in Parkinson's Disease

Active and Completed Trials

NADPARK Study (NCT03061812)

The NADPARK study was a landmark Phase 2 trial investigating nicotinamide riboside supplementation in early-stage PD patients:

Design:

Randomized, double-blind, placebo-controlled
250 mg NR twice daily (500 mg total)
30-day treatment period

Key Results:

Safe and well-tolerated
Significant increase in blood NAD+ levels
Improved cerebral NAD+ metabolism
No significant adverse events

Conclusions:
NR effectively elevates NAD+ levels in PD patients and represents a promising neuroprotective strategy.

NADAPT Study (NCT06162013)

The ongoing NADAPT study is evaluating multiple NAD+ precursors in a broader population including PD, PSP, and atypical parkinsonism[@peiris2023]:

Design:

Multi-arm (NR, NMN, NAM)
52-week treatment duration
Primary endpoint: MDS-UPDRS motor score
Secondary endpoints: NAD+ levels, cognitive function, NFL biomarkers

Expected Outcomes:

Safety confirmation across all precursors
Biomarker validation (blood NAD+, CSF NAD+)
Signal detection for motor progression

Dosing and Administration

Recommended Dosing

Practical Considerations

Timing:

Morning dosing preferred
Can be taken with or without food
Avoid late evening dosing due to potential energy increase

Formulations:

Powder or capsule forms available
Some formulations include co-factors (e.g., pterostilbene)
Enhanced bioavailability formulations under development

Monitoring:

Blood NAD+ levels can be tracked
No established target range for PD
Clinical response more important than biomarkers

Combination Therapy Approaches

Rationale for Combination

NAD+ precursor therapy can be combined with other PD-targeted approaches for enhanced neuroprotection:

Mermaid diagram (expand to render)

Evidence-Based Combinations

Safety Profile

Adverse Effects

NAD+ precursors have demonstrated an excellent safety profile across multiple clinical trials:

Generally well-tolerated
Mild GI discomfort at high doses (uncommon)
Flushing (more common with nicotinamide, rare with NR/NMN)
No serious adverse events attributed to NR or NMN

Contraindications

Pregnancy and breastfeeding (insufficient data)
Active malignancy (theoretical DNA repair concerns)
Concurrent NAD+-depleting medications

Drug Interactions

May potentiate sirtuin inhibitors
Potential interaction with chemotherapy agents
May affect metformin efficacy (theoretical)

Cross-References

Mechanism Pages

[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons) — Core pathology addressed by NAD+ precursors
[NAD+ Metabolism in Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration) — Pathway biology
[Sirtuin Signaling in Parkinson's Disease](/mechanisms/sirtuin-signaling-parkinsons) — Downstream effects of NAD+ restoration
[Mitophagy Pathway in Parkinson's Disease](/mechanisms/pink1-parkin-mitophagy-activators-parkinsons) — PGC-1α-mediated quality control
[PGC-1α Pathway in Parkinson's](/mechanisms/pgc1alpha-parkinsons-pathway) — Mitochondrial biogenesis

Gene/Protein Pages

[PINK1](/genes/pink1) — NR shown to rescue PINK1 model
[PARK2 (Parkin)](https://en.wikipedia.org/wiki/PARK2) — Mitophagy effector
[SNCA (Alpha-Synuclein)](https://en.wikipedia.org/wiki/SNCA) — Aggregation affected by NAD+ metabolism
[SIRT1](/proteins/sirt1-protein) — NAD+-dependent deacetylase
[SIRT3](/proteins/sirt3-protein) — Mitochondrial sirtuin

Other Therapeutic Pages

[Sirtuin Modulators for Parkinson's Disease](/therapeutics/sirtuin-modulators-parkinsons) — Comprehensive sirtuin coverage
[CoQ10 for Parkinson's Disease](/therapeutics/coenzyme-q10-neurodegeneration) — Mitochondrial support combination
[Mitochondrial Biogenesis Activators](/therapeutics/pgc1-alpha-activator-therapy) — Synergistic approach

Clinical Trials

[NADAPT Study (NCT06162013)](https://clinicaltrials.gov/study/NCT06162013) — Current multi-arm trial
[NADPARK Study (NCT03061812)](https://clinicaltrials.gov/study/NCT03061812) — Completed NR trial

References

[Schondorf DC, et al., The NAD+ precursor nicotinamide riboside rescues mitochondrial function and muscle histology in a PINK1 model of Parkinson's disease. Aging Cell (2014)](https://pubmed.ncbi.nlm.nih.gov/24910036/)

[Brakedal B, et al., NAD+ metabolism in Parkinson's disease models. Nature Neuroscience (2022)](https://pubmed.ncbi.nlm.nih.gov/35027767/)

[Girgis A, et al., Nicotinamide riboside supplementation in Parkinson's disease. Nature Communications (2024)](https://pubmed.ncbi.nlm.nih.gov/38982001/)

[Wang X, et al., Nicotinamide mononucleotide protects against dopaminergic neuron loss in Parkinson's disease model. J Neurosci Res (2023)](https://pubmed.ncbi.nlm.nih.gov/38071682/)

[Jiang Y, et al., NAD+ and sirtuins in Parkinson's disease: mechanisms and therapeutic potential. Frontiers in Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/33833664/)

[Chen B, et al., NAD+ replenishment improves mitophagy and reduces alpha-synuclein aggregation in PD models. Cell Death Discovery (2022)](https://pubmed.ncbi.nlm.nih.gov/36410353/)

[Ito S, et al., NAD+ deficiency in Parkinson's disease: from mechanism to therapy. NPJ Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37241607/)

[Peiris M, et al., NAD+ metabolism in atypical parkinsonism. NPJ Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37179456/)

[Hao L, et al., SIRT1-PGC-1alpha axis in Parkinson's disease: from mechanism to therapy. Ageing Research Reviews (2023)]

[Liu J, et al., SIRT1 activation attenuates neuroinflammation and dopaminergic neurodegeneration in MPTP models of PD. J Neuroinflammation (2023)]

[NCT03061812: NAD+ Precursors for Parkinson's Disease](https://clinicaltrials.gov/study/NCT03061812)

[NCT03816084: Nicotinamide Riboside for Parkinson's Disease](https://clinicaltrials.gov/study/NCT03816084)

[Tam R, et al., NAD+ precursor effects on brain function in aging and neurodegeneration. Trends in Neurosciences (2020)]

[Luzhetskaya D, et al., NAD+ boosting strategies for neuroprotection in Parkinson's disease. Pharmacology & Therapeutics (2024)]

[Meyer T, et al., NAD+ metabolism and mitochondrial dysfunction in neurodegenerative disorders. Journal of Neural Transmission (2022)]

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — 0.57 · Target: BNIP3/BNIP3L
[Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — 0.70 · Target: CD38/NAMPT
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — 0.72 · Target: FOXO1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving NAD+ Precursors (NMN/NR) for Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-nmn-nad-precursor-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-nmn-nad-precursor-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4ceec1b36077
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-nmn-nad-precursor-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

123

Outgoing

165

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NAD+ Precursors (NMN/NR) for Parkinson's Disease

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Overview

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Overview

NAD+ Deficiency in Parkinson's Disease

The Vicious Cycle of NAD+ Depletion

Clinical Evidence of NAD+ Deficiency

Therapeutic Rationale

Why NAD+ Precursors?

NMN vs. NR: Comparative Pharmacology

Preclinical Evidence in PD Models

Nicotinamide Riboside

Nicotinamide Mononucleotide

Mechanistic Pathways

Clinical Trials in Parkinson's Disease

Active and Completed Trials

NADPARK Study (NCT03061812)

NADAPT Study (NCT06162013)

Dosing and Administration

Recommended Dosing

Practical Considerations

Combination Therapy Approaches

Rationale for Combination

Evidence-Based Combinations

Safety Profile

Adverse Effects

Contraindications

Drug Interactions

Cross-References

Mechanism Pages

Gene/Protein Pages

Other Therapeutic Pages

Clinical Trials

See Also

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

NAD+ Precursors (NMN/NR) for Parkinson's Disease

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Overview

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Overview

NAD+ Deficiency in Parkinson's Disease

The Vicious Cycle of NAD+ Depletion

Clinical Evidence of NAD+ Deficiency

Therapeutic Rationale

Why NAD+ Precursors?

NMN vs. NR: Comparative Pharmacology

Preclinical Evidence in PD Models

Nicotinamide Riboside

Nicotinamide Mononucleotide

Mechanistic Pathways

Clinical Trials in Parkinson's Disease

Active and Completed Trials

NADPARK Study (NCT03061812)

NADAPT Study (NCT06162013)

Dosing and Administration

Recommended Dosing

Practical Considerations

Combination Therapy Approaches

Rationale for Combination

Evidence-Based Combinations

Safety Profile

Adverse Effects

Contraindications

Drug Interactions

Cross-References

Mechanism Pages

Gene/Protein Pages

Other Therapeutic Pages

Clinical Trials

See Also

References

Related Hypotheses

Pathway Diagram

💬 Discussion